RxDoctor Payments Data

Michael Horsley, MD

Ophthalmology · Sun City, AZNPI 1871704007

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,720 of the $9,088 with a category attached, or 62.9%. Aerie Pharmaceuticals, Inc. accounts for 71.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $5,959 and has fallen 94.1% since, to $352 in 2025.

$9,088in general payments, 2019–2025

Across 148 payments — averaging $61.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$6K
  • AbbVie$831
  • Alcon$761
  • NEW World Medical,inc.$382
  • Novartis$141
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$137
  • plus $361 from 7 others

What the payments were for

  • Consulting fees$3003%
  • Speaking & faculty fees$5,72063%
  • Food & beverage$3,06834%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,088 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$413,414
Medicare patients
596
Services billed
2,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost152$70,486
Prednisolone Acetate1,071$56,771
RhopressaNetarsudil Mesylate59$39,083
RocklatanNetarsudil Mesylat/Latanoprost61$34,415
Alphagan PBrimonidine Tartrate33$17,886
SimbrinzaBrinzolamide/Brimonidine Tart68$16,914
RestasisCyclosporine13$15,198
CombiganBrimonidine Tartrate/Timolol21$11,727
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$9,172
Latanoprost726$7,338
Brinzolamide41$7,020
Brimonidine Tartrate330$6,936
Travoprost34$6,151
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat289$4,521
Dorzolamide Hcl170$3,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$831$115,297219 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$6,476$73,497120 claims
AlconSimbrinza$761$16,91468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →